BR112015005876A2 - partículas derivadas de ácido propiônico com baixo ponto de fusão para uso em formas de dosagem oral - Google Patents

partículas derivadas de ácido propiônico com baixo ponto de fusão para uso em formas de dosagem oral

Info

Publication number
BR112015005876A2
BR112015005876A2 BR112015005876A BR112015005876A BR112015005876A2 BR 112015005876 A2 BR112015005876 A2 BR 112015005876A2 BR 112015005876 A BR112015005876 A BR 112015005876A BR 112015005876 A BR112015005876 A BR 112015005876A BR 112015005876 A2 BR112015005876 A2 BR 112015005876A2
Authority
BR
Brazil
Prior art keywords
dosage forms
propionic acid
low melting
acid derived
derived particles
Prior art date
Application number
BR112015005876A
Other languages
English (en)
Inventor
K Vuppala Murali
Bagchi Saumitra
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/789,797 external-priority patent/US20140256810A1/en
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Publication of BR112015005876A2 publication Critical patent/BR112015005876A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo patente de invenção: "partículas derivadas de ácido propiônico com baixo ponto de fusão para uso em formas de dosagem oral". a presente invenção refere-se a partículas derivadas de ácido propiônico com baixo ponto de fusão que são de fluxo livre e têm a sensação de queimação na garganta significativamente reduzida ou eliminada. são descritos um método de fabricação das partículas derivadas de ácido propiônico com baixo ponto de fusão; formas de dosagem contendo as partículas derivadas de ácido propiônico com baixo ponto de fusão; métodos de fabricação das formas de dosagem; e métodos de tratamento com o uso das formas de dosagem.
BR112015005876A 2012-09-18 2013-09-16 partículas derivadas de ácido propiônico com baixo ponto de fusão para uso em formas de dosagem oral BR112015005876A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702392P 2012-09-18 2012-09-18
US13/789,797 US20140256810A1 (en) 2013-03-08 2013-03-08 Low melting propionic acid derivative particles for use in oral dosage forms
PCT/US2013/059918 WO2014047001A1 (en) 2012-09-18 2013-09-16 Low melting propionic acid derivative particles for use in oral dosage forms

Publications (1)

Publication Number Publication Date
BR112015005876A2 true BR112015005876A2 (pt) 2017-07-04

Family

ID=49231643

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015005876A BR112015005876A2 (pt) 2012-09-18 2013-09-16 partículas derivadas de ácido propiônico com baixo ponto de fusão para uso em formas de dosagem oral

Country Status (8)

Country Link
EP (1) EP2897584A1 (pt)
CN (1) CN104640537A (pt)
AU (1) AU2013318356A1 (pt)
BR (1) BR112015005876A2 (pt)
CA (1) CA2884119A1 (pt)
HK (2) HK1209372A1 (pt)
RU (1) RU2015114540A (pt)
WO (1) WO2014047001A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015110511A (ru) * 2014-03-28 2016-10-20 МакНЕЙЛ-ППС, ИНК. Частицы производного пропионовой кислоты для прямого прессования
CN109956860B (zh) * 2019-03-08 2022-03-01 天津大学 一种布洛芬球形晶体的制备方法
CN112826798B (zh) * 2019-11-25 2023-04-07 上海博志研新药物技术有限公司 布洛芬药物组合物、制备方法及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497044A (en) 1974-03-07 1978-01-05 Prodotti Antibiotici Spa Salts of phenyl-alkanoic acids
DE3440288A1 (de) 1984-11-05 1986-05-07 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische zubereitung mit einem gehalt an mindestens einer schleimhautreizenden substanz oder dergleichen, insbesondere profen, sowie verfahren zu ihrer herstellung
US4923898A (en) 1984-12-26 1990-05-08 Analgesic Associates Analgesic, anti-inflammatory and skeletal muscle relaxant compositions comprising non-steroidal anti-inflammatory drugs and musculoskeletal relaxants and methods of using same
US4873231A (en) 1986-04-08 1989-10-10 Smith Walton J Decreasing the toxicity of an ibuprofen salt
CA2063141C (en) 1989-08-04 1997-03-04 Edward J. Roche Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
IT1246383B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
CA2061520C (en) 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
WO1994005260A1 (en) 1992-09-03 1994-03-17 Affinity Biotech, Inc. Taste-masking pharmaceutical compositions and methods for making the same
IT1264855B1 (it) 1993-06-21 1996-10-17 Zambon Spa Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici
ZA945944B (en) 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
TW442287B (en) 1995-06-13 2001-06-23 American Home Produits Corp Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac)
NZ333474A (en) 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
US6117452A (en) 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
FR2811912B1 (fr) 2000-07-21 2003-02-07 Gattefosse Ets Sa Procede d'enrobage de particules solides par un agent thermofusible, et particules solides ainsi enrobees
GB0113841D0 (en) 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
WO2005055983A2 (en) * 2003-12-09 2005-06-23 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
BRPI0419125A (pt) * 2004-12-10 2007-12-11 Council Scient Ind Res composição farmacêutica e processo para a preparação de uma composição farmacêutica
BRPI0718428A2 (pt) 2006-10-25 2013-11-12 Mcneil Ppc Inc Composição de ibuprofeno

Also Published As

Publication number Publication date
HK1212886A1 (zh) 2016-06-24
HK1209372A1 (en) 2016-04-01
RU2015114540A (ru) 2016-11-10
CA2884119A1 (en) 2014-03-27
WO2014047001A1 (en) 2014-03-27
EP2897584A1 (en) 2015-07-29
CN104640537A (zh) 2015-05-20
AU2013318356A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
BR112015026325A2 (pt) dosagem oral de compostos glp-1
PH12019500440A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
ECSP13012384A (es) Composición acuosa que contiene bromhexina
EA201291034A1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
BR112015029970A2 (pt) inibidores de cinase
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
BR112014009031A2 (pt) formulações de etanercept estabilizadas com íons de metais
BR112014026703A2 (pt) inibidores de dna-pk
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
BR112015001327A2 (pt) complexo cristalino de 1-ciano-2-(4-ciclopropil-benzil) -4-(beta-d-glicopiranos-1-il) -benzeno, métodos para sua preparação e o uso do mesmo para preparar medicamentos
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
BR112012022258A2 (pt) anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
BR112016006064A2 (pt) composição de pró-dentifrício, composição com base em glicerina, e, kit para terapia da mucosa oral
BR112013031652A2 (pt) métodos de tratamento para doenças retinais
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
DOP2016000076A (es) Tienouracilcarboxamidas cíclicas y usos de las mismas
BR112015005876A2 (pt) partículas derivadas de ácido propiônico com baixo ponto de fusão para uso em formas de dosagem oral
BR112014031306A2 (pt) composição farmacêutica e respectivos usos
BR112013027369A2 (pt) composições e métodos
AR093717A1 (es) Composiciones y metodos para el tratamiento de la caries dental
BR112015007095A8 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados
BR112015031585A2 (pt) composição farmacêutica
BR112015005968A2 (pt) formas de dosagem orais de liberação prolongada compreendendo partículas derivadas do ácido propiônico com baixo ponto de fusão

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06I Technical and formal requirements: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2531 DE 09-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.